Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels... Show more
SurgePays, Inc. (SURG) operates as a financial technology (fintech) and telecommunications company targeting underbanked and underserved consumers in the U.S. Its dual-segment model—Mobile Virtual Network Operator (MVNO) for brands like LinkUp Mobile and Torch Wireless, and Comprehensive Platform Services for point-of-sale (POS) solutions—provides a competitive edge through an extensive nationwide retail network of convenience stores and bodegas.
The company's proprietary POS platform facilitates prepaid wireless top-ups, SIM activations, fintech transactions, and emerging digital marketing tools, creating a vertically integrated ecosystem. This positions SURG uniquely against larger telecom incumbents, focusing on niche markets where traditional distribution falters. Medium-term strengths include scalable MVNE (Mobile Virtual Network Enabler) infrastructure for wholesale partnerships and data-driven retail solutions, though competition from established MVNOs and fintech players like Plaid or Green Dot remains intense. Expansion into high-margin SaaS-like offerings, such as Managed Marketing Services, bolsters structural resilience.
SurgePays faces pivotal events that could sway its trajectory. The April 14, 2026, conference call for Q4 and full-year 2025 results will likely update on subscriber growth and platform monetization, influencing sentiment amid prior affirmations of ambitious revenue paths.
Nasdaq compliance looms large: SURG must achieve $35 million market value of listed securities by September 14, 2026, and $1.00 minimum bid price by September 21, 2026, or risk delisting proceedings. Success here could restore investor access to capital markets; failure might erode liquidity.
Product rollouts like the Managed Marketing Services platform and Stored Value/Loyalty offerings promise recurring revenue from in-store digital media and customer retention. Ongoing LinkUp Mobile promotions aim to accelerate prepaid subscribers beyond 100,000, while Lifeline expansions via Torch Wireless tap stable government subsidies. Analyst views reflect balance: three firms' consensus "Hold" with a $9.75 target (1,300%+ upside potential), including a recent Strong Buy maintenance, though no major revisions noted recently.
SurgePays' fortunes hinge on fintech/telecom evolution toward embedded services and 5G adoption, where MVNOs thrive amid carrier consolidation. Regulatory tailwinds from Lifeline (federal subsidy for low-income connectivity) provide stability, contrasting the defunct Affordable Connectivity Program (ACP).
Macro sensitivities include interest rates and inflation, which strain underbanked consumers' discretionary spending on prepaid plans. Weaker demand cycles could pressure top-ups and activations, though recession-resilient subsidies buffer impacts. Geopolitical stability supports supply chain software alternatives to traditional wholesale models. Broader technology shifts, like digital payments and data monetization, align with SURG's POS ecosystem, but heightened competition demands execution.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It leverages advanced machine learning algorithms to analyze historical patterns, technical indicators, and market data, enabling users to spot developing trends, evaluate possible breakouts or reversals, and explore predictions across thousands of tradable instruments. The platform offers searchable prediction categories, historical performance context for each forecast, and customizable alerts to notify users of shifting sentiments. Ideal for both short-term traders and long-term investors, it provides data-driven insights to inform decisions. Explore the Trend Prediction Engine today to enhance your market analysis.
Looking to 2026, SurgePays eyes structural growth via retail network expansion to thousands more locations, scaling MVNO subscribers (LinkUp and Torch), and monetizing MVNE wholesale services. Prior guidance pointed to $225 million revenue, driven by Lifeline scaling, prepaid distribution, and ClearLine fintech, though recent filings omit reaffirmations amid compliance hurdles.
Key themes include margin expansion from owned payment rails and SaaS platforms, alongside data partnerships for targeted marketing. Cost efficiencies and bundled retail solutions (POS, loyalty, marketing) support profitability. Competitive threats from fintech disruptors persist, but underserved focus offers moat. Regulatory shifts in subsidies and Nasdaq status will shape sentiment; consensus targets imply optimism if executed. Capital allocation prioritizes compliance and organic scaling over M&A (mergers and acquisitions).
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Industry MajorTelecommunications
A.I.dvisor indicates that over the last year, SURG has been loosely correlated with TGL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SURG jumps, then TGL could also see price increases.
| Ticker / NAME | Correlation To SURG | 1D Price Change % | ||
|---|---|---|---|---|
| SURG | 100% | -11.33% | ||
| TGL - SURG | 37% Loosely correlated | +3.85% | ||
| RSKD - SURG | 36% Loosely correlated | +0.20% | ||
| RXT - SURG | 34% Loosely correlated | -2.86% | ||
| PCOR - SURG | 29% Poorly correlated | +0.38% | ||
| SKLZ - SURG | 29% Poorly correlated | -4.43% | ||
More | ||||
| Ticker / NAME | Correlation To SURG | 1D Price Change % |
|---|---|---|
| SURG | 100% | -11.33% |
| Major Telecommunications industry (60 stocks) | 15% Poorly correlated | +0.55% |
| Communications industry (80 stocks) | 13% Poorly correlated | +0.57% |
SURG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 43 cases where SURG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for SURG's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SURG advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on June 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SURG as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for SURG turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SURG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SURG entered a downward trend on June 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SURG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SURG's P/B Ratio (344.828) is very high in comparison to the industry average of (10.043). P/E Ratio (38.250) is within average values for comparable stocks, (31.574). Projected Growth (PEG Ratio) (0.474) is also within normal values, averaging (10.021). SURG has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.041). P/S Ratio (0.135) is also within normal values, averaging (6.667).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SURG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.